Limited sampling models for the pharmacokinetics of docetaxel

Clinical Drug Investigation

Volumn 13, Issue 5, 1997, Pages 247-254

  Lustig, V ^a   Rosing, H ^a   Van Warmerdam, L J C ^a   Huizing, M T ^a   Ten Bokkel Huinink, W W ^a   Dubbelman, A C ^a   Beijnen, J H ^a,b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; EXPERIMENTAL MODEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030943983     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199713050-00004     Document Type: Article

References (23)

1. Schumacher GE. Choosing optimal sampling times for therapeutic drug monitoring. Clin Pharm 1985; 4: 84-92
2. Moore MJ, Erlichman C. Therapeutic drug monitoring in oncology: problems and potential in antineoplastic therapy. Clin Pharmacokinet 1987; 13: 205-27
3. Hamilton SF, Evans WE. Accuracy of using pre- and post-dose gentamicin serum concentrations to estimate pharmacokinetic parameters and adjust doses in children and adolescents. Ther Drug Monit 1981; 3: 57-61
4. Koup JR, Sack CM, Smith AL, et al. Hypothesis for the individualisation of drug dosage. Clin Pharmacokinet 1979; 4: 460-9
5. Eksborg S. Anthracycline pharmacokinetics. Limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin). Acta Oncol 1990; 29: 339-42
6. Ratain MJ, Robert J, Vijgh WJF van der. Limited sampling models for doxorubicin pharmacokinetics. J Clin Oncol 1991; 9: 871-6
7. Ratain MJ, Vogelzang NJ. Limited sampling model for vinblastine pharmacokinetics. Cancer Treat Rep 1987; 71: 935-9
8. Evans W, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989; 16: 327-36
9. EORTC Pharmacokinetics and Metabolism Group. Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. Eur J Clin Oncol 1987; 23: 1083-7
10. Van Warmerdam LJC, Van den Bemt BJF, Ten Bokkel Huinink WW, et al. Dose individualisation in cancer chemotherapy: pharmacokinetic and pharmacodynamic relationships. Cancer Res Ther Control 1995; 4: 277-91
11. Van Warmerdam LJC, Ten Bokkel Huinink WW, Maes RAA, et al. Limited sampling models for anticancer agents. J Cancer Res Clin Oncol 1994; 120: 427-33
12. Bissery MC, Nohynek G, Sanderink GJ, et al. Docetaxel: a review of preclinical and clinical experience. Anticancer Drugs 1995; 6: 339-68
13. Huizing MT, Misser VH, Pieters RC, et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13: 381-404
14. Hill BT, Whelan RD, Shellard SA, et al. Differential cytotoxic effects of docetaxel in a range of mammalian tumour cell lines and certain drug resistant sublines in vitro. Invest New Drugs 1994; 12: 169-82
15. Munkarah A, Chuang L, Lotzova E, et al. Comparative studies of taxol and taxotere on tumor growth and lymphocyte functions. Gynecol Oncol 1994; 55: 211-6
16. Pazdur R, Newman RA, Newman BM, et al. Phase I trial of taxotere: five-day schedule. J Natl Cancer Inst 1992; 84: 1781-8
17. Rosing H, Koopman-Kroon FP, Lustig V, et al. Determination of docetaxel in human plasma by semi-automated reversed-phase high performance liquid chromatography. Ann Oncol 1996; 7 Suppl. 1: 95
18. Proost JH, Meijer DKF. MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992; 22: 155-60
19. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12
20. NCSS® package. version 5.0; J.L. Hintze, East Kaysville, Utah, USA, 1991
21. Quattro Pro® package. version 4.00; Borland International, Scotts Valley, CA, USA, 1992
22. Bruno R, Sanderink GJ. Pharmacokinetics and metabolism of taxotere. Cancer Surv 1993; 17: 305-13
23. Bruno R, Vivier N, Vergniol JC, et al. A population pharmacokinetic model for docetaxel: model building and validation. J Pharmacokinet Biopharm 1996; 2: 153-73